Good day, everybody. Welcome to UBS Global Biopharma Conference in London. My name is Ash Verma. I cover SMID-cap biotech and spec pharma. I am really excited to have Exelixis as the next company. I have Andrew Peters, who is the SVP of strategy and investor relations. Thank you, Andrew, for joining us.
Yeah, thank you for the invite.
Yeah, Exelixis has been a pretty incredible story, just looking at the stock chart. I mean, what a turnaround you've had, going from back when you settled on CABOMETYX and then Zanza, and sort of building out the pipeline. Maybe if you can just highlight a couple of key topics in terms of some of the recent updates that you've had from the third quarter earnings, and then we can take it from there.
Yeah, great. Thanks again for the invite. Happy to be here as an alumnus of UBS myself. It is always good to be on stage in this seat versus that seat. As a reminder, I am going to be making some forward-looking statements today, so please see relevant disclosures around risks to our business in our filings with the SEC. Yeah, it is a really exciting time to be at Exelixis. It is kind of that pivot point or turning point for the company as we are transitioning from a single-product company with CABOMETYX to now a multi-franchise company with zanzalintinib in our potential approval and PDUFA date early next year. One of the things we say all the time, biotech, biopharma is a really tough business. Finding one successful franchise is hard.
Doing it a second time is even more difficult, and that's something that I really think we internalize and are particularly proud of and kind of all the work and excitement that we have internally. So, third quarter call, really it's kind of about two things, the Cabo business continuing to kind of hum along, and then Zanza development, Zanza pre-commercial activity, and then kind of our internal efforts around early pipeline and expense management, expense discipline, and kind of this through line that we run Exelixis like a business and not a biotech, and that's something that we really take to heart and try and do. So, excited times, but our focus is just on execution. We're going to keep our head down and keep going.
Yeah, that's great. So maybe I'll spend a little bit of a few questions on CABOMETYX first. So, I think there has been a few datasets that have come out, particularly the LITESPARK-011 study, and some of the feedback that we've heard from physicians is that, as that regimen starts to get used in more second line, Cabo moves more to earlier line. Is that sort of similar to the dynamic that you're experiencing as well? And just from your vantage point, if you can talk about what's sort of the flow of patients that you would benefit out of this.
Yeah. So I think you're referring to the LITESPARK-011 data that came out at ESMO earlier this year. And taking a step back, I think ESMO was great in a sense that there was a lot of data coming out in RCC, and it's kind of the market leaders in RCC. It's heartening to see a lot of interest in the space and a lot of kind of growing just combinations, modalities, all of that stuff. It's something that we're certainly focused on and paying attention to. So great to see. Some kind of learnings there, I guess, before I talk about LITESPARK-011, one of the things in the broader RCC space that we certainly focus on is LITESPARK-012 and the failure there. And what that really does is it opens the door for opportunities for Exelixis to invest in the front line.
So that's something, kind of an area to certainly stay tuned over the next several months as we think about how to kind of implement a strategy there. But your question on LITESPARK-011 and kind of the second -line dynamic, really the full dataset that read out at ESMO was really kind of as expected. They saw a PFS benefit, but didn't see a statistically significant survival advantage. And it kind of comes down to one of those age-old questions in oncology where, is it better to sequence or is it better to combine? Historically, the way that you answer that question is overall survival. Because if you take a look at, say, CABOMETYX or a TKI on its own in second line, and then belzutifan on its own in third line, you're 10, 11 months, five, six months.
The totality, the absolute PFS of the sequence approach is actually a little bit longer than the combined approach, then you layer on the tox and tolerability issues and all of that. It becomes a real kind of question for patients and physicians in a conversation to have, especially in the context of no overall survival. That is some of the kind of market backdrop that we expect. The second part is certainly the case where we talked about, if those patients and physicians are likely to get LEN/BEL second line, means they most likely will not get LEN first line. That kind of first -line market share that we are continuing to fight for every single day in the market, that should probably benefit us. Again, as all of the data continue to kind of stream out of ESMO, not a lot really changed.
We will probably see some incremental share in first line, depending off if we lose some share second line. It is kind of that dynamic is what we are paying attention to.
All right. Okay. If I can just follow up, that is an interesting nugget that you could pursue more opportunities in the first line. I mean, is it more for Cabo or some early stage pipeline?
No, no, Zanza. I guess big picture, I mean, the way that we are thinking about it is we have the seven pivotal studies with Zanza right now. We call it wave one. The totality of those opportunities, we think, not only can let us kind of grow through Cabo, but grow much better than Cabo. Then we are layering on the second wave of Zanza opportunities, which we think have the potential to be much bigger. I would certainly lump that frontline RCC study that we are kind of putting the finishing touches on, so to speak, as one of the key anchor points of that second wave of Zanza.
Got it. Okay. Perfect. I know there's been some competitor update on the HIF-2α, casdatifan didn't really generate the competitive dataset in second -line RCC. Just like your thoughts on that, curious to see, they have a first line study that's reading out in 2028. Just curious from your perspective, is there could be sort of like a revival of this thesis that is more competition?
Yeah. The HIF space is certainly one we're focused on. Obviously, we have two pivotal studies that Merck is running with Zanza and BELZ. Totality of the data, we tend to see those two molecules as probably more similar than different, with Zanza as the kind of best-in-class TKI choice. I mean, our perspective on the evolution of how RCC patients will be treated in the future is that Cabo's the TKI of choice for the 2020s, and Zanza will be the TKI of choice for the 2030s.
That's a dynamic that, again, is going to kind of flow through, one, these wave one studies, but the wave two studies as well, as we think about not necessarily kind of how patients are managed and what their journey looks like today from a first line, second line, third line perspective, but the way we approach development is, how are patients going to be treated? What is their journey like with RCC going to be like in 2032, 2033, where more patients are likely to get adjuvant pembro? So that frontline opportunity set is just functionally different than, say, how they're managed today or how they were managed two years ago. So that kind of dynamic changes.
Certainly we're monitoring kind of everything that's going on competitively in the space, but we think we have some very competitive trials in LITESPARK-033 with Merck, that's kind of that frontline post-adjuvant space.
Yeah.
Then 34, that later line space. Again, we think the best way to view that lens is how are patients going to be managed in the future? Those two studies, I think, are really poised to define standards of care in a way that just doesn't exist today. As an example, with pembro now having a survival advantage, we're seeing more and more patients getting KEYTRUDA post-adjuvant or as part of their adjuvant care. Once their tumor does come back, though, the question is, what should they get? Right now, we think patients are likely getting Cabo more by default than anything because there's never really been a dataset in that population. So again, LITESPARK-033 is poised to define a standard of care there.
So again, it's an example of the approach that Exelixis takes in trying to be that leader in RCC, and we're going to continue to invest to be the leaders in RCC.
Great. Okay, perfect. So just switching gears to the NET indication. I know you've had a pretty successful launch here, just what a function of the indolent disease is that the patient inflow into the funnel has been a little bit slower in the last couple of quarters. You have previously outlined this as a roughly $400 million in terms of the peak sales opportunity. Do you think that is still a sustainable goal?
Yeah. So there are a couple dynamics there. I think the first is, we've said that the NET market, that second -line or later -line oral NET market's probably about a $1 billion TAM. What we're going to do is try and fight for every single market share point of that that we can. One, the CABINET data certainly speak for themselves in terms of the potential positive impact in patient lives. But two, given that it's a largely generic market, our share of voice is something that is particularly high and has enabled us to really grab that accelerated share.
As it relates to kind of that temporal aspect of the launch that you talked about, how PJ outlined it on the last or second two earnings calls ago, it is more of kind of a temporal dynamic in what the shape of the launch curve looks like, and it is not necessarily where that destination is. It is probably more of the how we get there. And really what that is a function of the nature of the NET patient's journey again. So if you think about a normal lung cancer or something, patients come in, say, every three months for a scan to see is their tumor continuing to shrink, staying the same size, or unfortunately growing. And if it is growing, kind of a treatment decision is made at that time to switch to a new therapy, look at a new dose, or those things.
Because NET is a more indolent disease, that scan interval, because the tumor is less aggressive in how it grows, can be longer, four, five, six months, potentially longer. And so that opportunity set, if the patient's tumor is growing, to kind of come onto a new therapy is just temporally right-shifted. Similarly, because the disease is not as aggressive, what we are finding is, especially in, say, some pockets of the community landscape, treatment decision is something like, "Let us put you on Cabo, but before that, why do not you wash out for a month or so from your previous therapy, recover, get stronger?" Because all of these anti-cancer therapies unfortunately do come with some side effects. So again, our market share data and these patient share data that we have outlined would certainly suggest that we are capturing those patients.
It is just the time course of when they come onto therapy, temporally is a little bit right-shifted. And so our view, kind of that aspirational goal number stays the same, just the shape and how we get there is maybe a little different.
Perfect. Okay, great. That is great. And then one more aspect to Cabo has been just around the 340B impact to pricing. So yeah, they are sort of similar, I guess, on the veins of just a little bit more sporadic in terms of the impact to the recently quarterly sales number. Has that sort of variability died down now? Just going forward, what should we assume?
Yeah. I mean, it's funny. 340B is a dynamic that's not an Exelixis issue. It's frankly an industry issue. The last data that I've seen is it's functionally an $80 billion-$100 billion wealth transfer from the manufacturers to the hospitals. The industry collectively is trying to figure out how those dynamics work, and each company, Exelixis included, is also trying to figure out how do we best manage our business. You mentioned kind of the variability. I think we call it choppiness or something functional like that. The analogy I always like to think about is it's kind of a tennis match where the manufacturers do something, the hospitals do something, the 340B entities do something, we do something.
It's kind of this back and forth, and the variability or choppiness or whoever kind of depends on where we are in that relative back and forth. Every company implements kind of their own little strategies around how to ensure that the 340B program is being appropriately used. That kind of influences some of it. Obviously, there's some seasonal dynamics, there's some calendar seasonal dynamics. There's just a lot of kind of back and forth. Again, we give annual guidance, not quarterly guidance, in part because we think that allows us to have the best kind of sense of where we'll shake out over the course of the year. You layer on kind of the intra-quarter choppiness that we and everyone see in the business.
Great. Okay. Just one more question on Cabo before we go to Zanza. Yeah, good to see the settlement with Azurity. I know there's another competitor out there, Handa. Would sort of the same dynamic apply for this competitor as they're trying to enter the market?
Yeah. I mean, again, kind of don't want to get in ahead of any potential legal strategy dynamics. The way that I think about Cabo and think whether it's 340B or real generics, we manage the business with January 1st, 2031 as kind of the best guess on when a generic Cabo is going to be available. Beyond that, like any successful product, we're continuing to face legal challenges. My visualization of it is there's a lot of balls in the air that we're juggling, but we have a pretty good sense of them, and we're kind of handling them as they come in.
Yeah.
That's everything.
All right. Okay, great. Let's talk about zanzalintinib. Just maybe on the CRC approval, just heading into the decision for this Zanza plus Atezo in third -line plus opportunity. I mean, can you kind of frame on potential label scenarios here? I know based on how the data has played out, so you had the ITT population, which was positive, the NLM subgroup didn't really hit for whatever reason. Is this, are you confident that you would get full label? The reason why I ask is, there's some investors who think that there's some gray area there, but FDA doesn't give approval based on the presence or absence of metastasis in an individual organ. It's very, very rare to see that. The [inaudible] is one example of it, but I haven't seen any of that.
Just help us understand, as you're getting towards the potential label scenarios, what that might entail.
Yeah. So kind of for a little bit of background for those who aren't familiar, when we designed and ran the 303 study, it was really, again, we wanted to be on the cutting edge of how patients are treated. Our observation had been, if you looked at the five or so prior studies that had looked at, say, checkpoints in this third-line plus setting, there seemed to be a potentially differentiated benefit in patients without liver metastases. We designed the study to kind of look both at an ITT basis as well as that non-liver met group. Again, one of the challenges with kind of post-hoc, really empiric data, not necessarily mechanism-related data.
Turns out that non-liver met dynamics just probably less of a relevant point, at least when you take a drug like Zanza, which the 303 data showed on an ITT basis, patients lived longer if they took Zanza/Atezo relative to the standard of care. That non-liver met group's probably less relevant, at least in our combination. As it relates to kind of this label issue, don't want to really speculate on it, but one, the ITT population, which is the study population that we filed on, was inclusive of both liver met and non-liver met patients. The dynamic that you're talking about where there is kind of a more selected patient population, that tends to come out of instances where there's a particular subgroup driving a lot of efficacy.
I think the most prominent one or common one that comes to mind is the PARPs in kind of this BRCA population versus HRD versus all comers, where that BRCA mutant population really drove the efficacy overall. If you look at the 303 data and the forest plots, it's this consistency of effect across all of the different subgroups, NLM, liver mets, prior Avastin, pretty much every way you could look at the data, there's this consistency of effect, and that's actually something that really kind of jumps out when we do market research with KOLs and kind of ad boards and stuff. That's something that I think differentiates the combination versus some of the other options out there for patients. We're excited about the potential approval.
It's going to be kind of that foundation for Zanza that we're going to build on from there, not only in CRC, because we have a couple of other studies ongoing there, but kind of the Zanza development program in general.
Right. Okay, perfect. Yeah. Then, just on the market size here, the latest earnings call, you outlined that there are roughly 23,000 patients, right? Just bear with me. I have been looking at this for a while, maybe for a long time, and I think some of the prior data cuts that you have presented on this market opportunity, like if I go back like last three years, we've seen that this number was 27,000 or 31,000. I can say, the latest is 23,000. I'm more trying to understand, is that like a firm assumption? Is there some variability around as you're getting close to the-
Yeah, I think you are kind of maybe reading into it a little bit incorrectly there. What we have done is we have kind of said we think it is about a $1.5 billion market, just TAM. The numbers you talked about, I think you are getting into drug treated versus drug treatable, and then 2025 or 2026 patients and 2035 patients. Kind of the way we view the world when we really dig in from a market research perspective, it is kind of that patient funnel. The epi changes over time, so obviously there are some differences between how many patients now versus how many patients in the future. Then there is drug treatable versus drug treated, which are kind of two different cuts of that same data. I think what you are referring to is probably more of those dynamics than anything.
We have been pretty consistent about it being a $1.5 billion market in general. Again, our job is going to be to fight for every market share point we can within that segment. Yeah.
The $1.5 billion is the whole TAM multiplied by what the branded pricing would be? Is that
Yeah.
Okay. You would take a share of that market?
Yeah. Again, for background of folks maybe less familiar, one of the interesting things about CRC and later line CRC is that given that it's much more community-based than academic KOL-based, market share is a little bit more fragmented than I think many people think. About a third of patients receive that SUNLIGHT regimen, a third get a TKI, and then a third chemo and a bunch of other stuff. When we talk about TAM, same methodology in NETs, we look at drug treated patients times the math is pretty simple. Drug treated patients assumed duration and then assumed contemporary price. That's kind of that $1.5 billion that we think's a good north star, so to speak, for us to kind of go in and try and take as much share as we can.
Yeah. Just in terms of the launch opportunity, what type of launch prep do you have going on for this? I guess the community launches typically, from what I've seen, can be a little bit gradual compared to, let's say, more academic type settings. When you think about that market dynamic and then the current market composition around the SUNLIGHT or the TKI chemo, where do you think you would take share from to begin with?
Yeah. Our goal is to kind of take share across all those segments. Certainly, we think that we have a very compelling data set, and really that's what drives use in oncology is the data. But when you layer on, say, factors like I mentioned before, efficacy despite prior Avastin use, which is kind of one of the factors that, say, impacts like SUNLIGHT regimen where, you know, given that their data seem to show that patients do a little worse if they've received prior Avastin, with 80%+ of patients receiving one or two courses of Avastin prior to that third-line plus setting, the real-world implications here in the U.S. at least are challenged there. Then, again, a lot of these patients will have been on chemo for their first line and second line, so Zanza/Atezo provides kind of this chemo-free option.
Yeah.
The third one that we've certainly talked about, it kind of tends to come up again and again in these ad boards and market research, et cetera, is kind of this checkpoint-containing dynamic. As we move towards the community, you see one of these things where patients will be out watching the Super Bowl, some big event, and they'll see commercials for KEYTRUDA or pembro or Atezo or all of these, and go to their oncologist and say, "Hey, is this something that I could get for my cancer?" Historically, the answer has been, "Unfortunately, for your tumor type, this sort of drug is not available." But 303 potentially enabled that.
Given that these community docs don't just focus on CRC, where the checkpoints haven't been used historically, that they see many different types of cancers, the level of familiarity, they're already writing scripts for Atezo or KEYTRUDA or YERVOY, et cetera. It's just a little bit of a different dynamic there. You take that, then you layer on the fact that we upsized our commercial organization earlier this year, in part to continue to accelerate the NET launch, but again, have those boots on the ground, so to speak, ahead of the Zanza launch, given the overlap in those prescriber populations. It's one that we think we're particularly well set up for, and we're going to be ready day one post-approval.
Great. Awesome. I'll just open it up in the audience as well, if you have any questions, anybody. Otherwise, I have a few more that I'll ask. Maybe just on the non-clear cell RCC. This trial, it's been delayed a few times, which is kind of like a positive signal, right? As you think about the readout here, just if you can kind of remind the audience. You're expecting 1Q readout based on the events that are accruing. Is that like are you certain and getting to a reasonable amount of precision on that readout, or?
Yeah. I mean, it's an event-based endpoint, so literally we're counting events as they're coming in. I think Dana talked about on the last call, based on kind of the events, we're expecting clinical cutoff shortly. Once you hit clinical cutoff, clean the data, et cetera, then you top-line it. That's what gives us confidence around that 1Q. If we see clinical cutoff around year-end, that's what's driving that 1Q timeline.
Could that come at ASCO GI or at the conference?
Can't speculate on when.
Okay.
I mean, the honest answer is it's going to take however long it takes to kind of clean the data, get the database ready to kind of get that envelope open—
Yeah.
—clean the data and top-line it, so 1Q is our best guess.
Got it. Okay. Then, just in terms of the benchmarks here, particularly for the control arm, I know some of the Sutent data that exists from before is pretty old. Could there be a surprise in the control arm here?
Yeah, can't speculate on data. But I think you called out one of the dynamics that I think is somewhat unique in non-clear cell RCC, just there's not great data across the board. If you go back to when we were designing the study, one of the things that candidly surprised me is that there had never been a phase III study in this setting.
Yeah.
So we have a chance to really kind of plant a flag in the ground and define a standard of care, again, this theme that I mentioned earlier in our conversation. So, it's really a chance to say, with level 1 evidence in a large global randomized study, this is the standard of care. Whereas right now, treatment choices are really driven by single-arm, unrandomized, relatively small phase II studies in NCCN guidelines. So we have a chance to define with level 1 evidence what the standard of care in non-clear cell RCC should be.
It again kind of provides that next step in the foundation of Zanza that as we look out, what the next several years look like for us, it's really going to be about that breadth of opportunity for Zanza, not only the seven pivotal studies of wave one, but wave two coming in. So, as we see the company transitioning from Cabo to multi-franchise to Zanza to kind of what's next, that's kind of that growth trajectory that we're looking towards.
Great. With that, we are out of time. Unless anybody had any questions, checking one more time. Nope, I think we are good.
All right. Thank you.
All right. Yeah. Thank you so much for this. This was super helpful. Thank you.